

**The Arizona Chapter of the American Academy of Pediatrics**  
**Project Firstline Mini Podcast Series**  
*Special limited-edition podcast series, Infectious Dialogues: Timely Topics in Infection and Prevention Control*

May 1st – June 30th 2024

**Attendees: Prior to the start of the activity, please review the below information to ensure successful participation in this enduring educational series**

**Accreditation Statement**

The Arizona Chapter of the American Academy of Pediatrics is accredited by the Arizona Medical Association to provide continuing medical education for physicians.

The Arizona Chapter of the American Academy of Pediatrics designates this enduring educational activity for a maximum of 1.25 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity.

**Purpose of Course**

This podcast series has been designed with the goal to develop, maintain, and increase the knowledge, skills, and professional performance of pediatric healthcare providers in the area of infection prevention and control. Participants will review best practices for infection prevention and control within hospital and practice settings.

**Learning Objectives**

At the conclusion of this activity, learners will be able to:

Podcast 1: Update on congenital syphilis transmission recognition, prevention and treatment:

1. Compare different protocols for testing and treatment for congenital syphilis, based on maternal and neonatal risk factors
2. Identify important clinical features and treatment strategies for active congenitally-acquired syphilis in the first year of life
3. Discuss important infection prevention strategies and screening techniques to prevent congenitally-acquired syphilis

Podcast 2: Update on perinatal hepatitis C transmission recognition, prevention and treatment:

1. Review the new testing strategy for perinatal hepatitis C exposure
2. Identify important clinical features and treatment strategies for active perinatally-acquired hepatitis C
3. Discuss infection prevention strategies important in the management and prevention of hepatitis C

Podcast 3: Update on COVID-19 variants, vaccines (and pediatric vaccine schedule), disease/virulence:

1. Identify current COVID-19 variants and their associated clinical features
2. Discuss infection prevention strategies based on updated COVID-19 vaccine recommendations
3. Apply current recommendations for infection prevention of COVID-19 in office, emergency department and hospital settings

**Target Audience**

Pediatric healthcare professionals, including general pediatricians, pediatric subspecialists, residents/fellows, nurses, and physician assistants

**Disclosure of Commercial Support for AzAAP CME Activities**

No commercial support is associated with this activity. The AzAAP gratefully acknowledges support for this mini podcast series in the form of an unrestricted educational grant from the American Academy of Pediatrics.

*\*Sponsors are neither recommended nor endorsed by the Arizona Chapter of the American Academy of Pediatrics.*

**Disclosure of Financial Relationships and Mitigation of Conflicts of Interest for AzAAP CME Activities**

In order to support the professional needs of its members, the AzAAP Continuing Medical Education (CME) program develops, maintains, and improves the competence, skills, and professional performance of pediatricians and pediatric healthcare professionals by providing quality, relevant, accessible, and effective educational experiences that address gaps in professional practice. The AzAAP CME program strives to meet the educational needs of pediatricians and pediatric healthcare professionals and support their lifelong learning with a goal of improving care for children and families.

The AzAAP recognizes that there are a variety of financial relationships between individuals and ineligible companies that require review to identify possible conflicts of interest in a CME activity. The “AzAAP Policy on Disclosure of Financial Relationships and Mitigation of Conflicts of Interest for AzAAP CME Activities” is designed to ensure quality, objective, balanced, and scientifically rigorous AzAAP provided or jointly provided CME activities by identifying and mitigating all potential conflicts of interest prior to the confirmation of service of those in a position to influence and/or control CME content. AzAAP has taken steps to mitigate any potential conflicts of interest. The purpose of this policy is to ensure all potential conflicts of interest are identified and mechanisms to mitigate them prior to the CME activity are implemented in ways that are consistent with the public good. The AzAAP is committed to providing learners with commercially unbiased CME activities.

All AzAAP CME activities will strictly adhere to the *Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accrediting Continuing Education*. In accordance with these Standards, the following decisions will be made free of the control of an ineligible company: identification of CME needs, determination of educational objectives, selection and presentation of content, selection of all persons and organizations that will be in a position to control the content, selection of educational methods, and evaluation of the CME activity.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

*All individuals in a position to influence and/or control the content of AzAAP CME activities are required to disclose to the AzAAP and subsequently to learners that the individual either has no relevant financial relationships or any financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in CME activities. \*An ineligible company is defined as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Listed below are the disclosures provided by individuals in a position to influence and/or control CME activity content. **All of the relevant financial relationships listed for these individuals have been mitigated. This activity may discuss or demonstrate pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or “off-label” use of an approved device or pharmaceutical.***

<b>Name</b>	<b>Role</b>	<b>All Financial Relationships</b> (Please indicate Yes or No)	<b>Name of Ineligible Company*</b> Please list name(s) of entity AND Nature of Financial Relationship(s) (Please list: Research Grant, Speaker's Bureau, Stock/Bonds excluding mutual funds, Consultant, Other – identify)
Sean Elliott, MD, FAAP, FPIDS	Activity Director/Planning Member/Faculty	No	N/A
Dr. Richard Engel	Abstract Reviewer/COI Resolver	No	N/A
Haley St Paul	Planning Member/ Abstract Reviewer	No	N/A
Stacy Williams	Planning Member/ Abstract Reviewer	No	N/A
Lauren Valdiviezo	Planning Member/Abstract Reviewer	No	N/A

**Disclosure of Unlabeled Use**

This activity may discuss or demonstrate pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or “off-label” use of an approved device or pharmaceutical. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

**Disclaimer**

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

**Product-Specific Advertising / Links to Product Websites**

No product-specific advertising of any type appears in this activity. No links to product websites appear in this activity.

**List of Principal Faculty and Credentials**

Dr Sean Elliott, MD, FAAP, FPIDS

**Method of Participation, Minimum Performance Level, and Credit Claiming**

This limited-edition podcast series is available through May 31st, 2024, via AzAAP's website, Apple Podcast, Spotify, iHeartRadio, and other podcast streaming platforms. Each episode contains CME content, and learners can earn credit after successful completion of the full series. In order to receive CME credit, participants must review the activity content by the deadline, attest to listening to the educational content in its entirety, and complete the evaluation.

**Need more help?**

If you need further assistance, please call the AzAAP office anytime Monday–Friday at 602-532-0137 ext. 417 from 9:00 am and 5:00 pm MST or email us at [Haley@azaap.org](mailto:Haley@azaap.org).

**Provider Contact Information**

If you have questions about this course or encounter technical problems, please contact [Haley@azaap.org](mailto:Haley@azaap.org).

**Privacy and Confidentiality Statement**

At the Arizona Chapter of the American Academy of Pediatrics (AzAAP), we take the issue of privacy very seriously. We do not sell, distribute, barter, or transfer personally identifiable information obtained from a user to a third party without your consent. Any information collected on during this course is only used for the purpose stated. The email list for this project is only for important communications, and your e-mail address will not be sold or provided to third parties. You will not receive advertising or promotional materials on this email list. Individual learners must provide consent in order to share contact information with ineligible companies.

The AzAAP may use “cookie” technology to obtain non-personal information from its online visitors. We do not extract personal information in this process, nor do we provide this information to third parties. We also do not contact you based on the information in your cookie file.

The AzAAP has taken steps to make all information received from our online visitors as secure as possible against unauthorized access and use. All information is protected by our security measures, which are periodically reviewed.

*Updated November 2021*